Invivyd (NASDAQ:IVVD) Price Target Lowered to $10.00 at HC Wainwright

Invivyd (NASDAQ:IVVD) had its price target dropped by analysts at HC Wainwright from $15.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th.

Invivyd Stock Up 3.7 %

NASDAQ:IVVD opened at $0.77 on Wednesday. The firm has a market capitalization of $91.79 million, a PE ratio of -0.39 and a beta of 0.65. Invivyd has a twelve month low of $0.72 and a twelve month high of $5.20. The stock’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $1.26.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after purchasing an additional 75,780 shares in the last quarter. State Street Corp raised its position in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Invivyd in the 3rd quarter worth approximately $27,000. Cubist Systematic Strategies LLC lifted its holdings in Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Invivyd during the second quarter worth about $115,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.